Ayana Pharma - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsAyana Pharma

Ayana Pharma

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Doxorubicin	Doxorubicin	2021-10-12		Myeloid leukemia acute , Breast neoplasms , Ovarian neoplasms , Thyroid neoplasms , Gastrointestinal neoplasms , Lung neoplasms , Multiple myeloma , Neuroblastoma , Precursor cell lymphoblastic leukemia-lymphoma , Urinary bladder neoplasms , Osteosarcoma , Hodgkin disease , Soft tissue neoplasms , Kaposi sarcoma , Wilms tumor

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

b-cell lymphoma

,

hodgkin disease

,

,

breast neoplasms

,

,

chemotherapy-induced febrile neutropenia

,

mucinous adenocarcinoma

,

ductal carcinoma breast

,

inflammatory breast neoplasms

,

non-hodgkin lymphoma

,

mantle-cell lymphoma

Doxorubicin hydrochloride

b-cell lymphoma

,

hodgkin disease

,

breast neoplasms

,

,

,

chemotherapy-induced febrile neutropenia

,

mucinous adenocarcinoma

,

ductal carcinoma breast

,

inflammatory breast neoplasms

,

non-hodgkin lymphoma

,

mantle-cell lymphoma

breast neoplasms

,

,

triple negative breast neoplasms

,

,

,

kidney neoplasms

,

adenoviridae infections

,

,

hodgkin disease

,

,

,

multiple myeloma

,

plasma cell neoplasms

,

invasive hydatidiform mole

,

hypersensitivity

,

hepatocellular carcinoma

,

,

,

,

mullerian mixed tumor

,

,

urinary bladder neoplasms

,

serous cystadenocarcinoma

,

peritoneal neoplasms

,

,

t-cell lymphoma

,

,

,

primitive neuroectodermal tumors

,

primitive neuroectodermal tumors peripheral

,

neuroectodermal tumors

,

renal cell carcinoma

,

colorectal neoplasms

,

,

,

triple negative breast neoplasms

,

fallopian tube neoplasms

,

non-hodgkin lymphoma

,

endometrial neoplasms

,

large b-cell lymphoma diffuse

,

b-cell lymphoma

,

,

,

breast neoplasms

,

ovarian neoplasms

,

ovarian epithelial carcinoma

,

,

,

hand-foot syndrome

,

drug-related side effects and adverse reactions

,

follicular lymphoma

,

Hydroxydaunomycin

,

,

,

kidney neoplasms

,

adenoviridae infections

,

,

hodgkin disease

,

,

,

multiple myeloma

,

plasma cell neoplasms

,

invasive hydatidiform mole

,

hypersensitivity

,

hepatocellular carcinoma

,

,

,

,

mullerian mixed tumor

,

,

urinary bladder neoplasms

,

serous cystadenocarcinoma

,

peritoneal neoplasms

,

,

t-cell lymphoma

,

,

,

primitive neuroectodermal tumors

,

primitive neuroectodermal tumors peripheral

,

neuroectodermal tumors

,

renal cell carcinoma

,

colorectal neoplasms

,

,

,

triple negative breast neoplasms

,

fallopian tube neoplasms

,

non-hodgkin lymphoma

,

endometrial neoplasms

,

large b-cell lymphoma diffuse

,

b-cell lymphoma

,

,

,

breast neoplasms

,

ovarian neoplasms

,

ovarian epithelial carcinoma

,

,

,

hand-foot syndrome

,

drug-related side effects and adverse reactions

,

follicular lymphoma

,

© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use